Living donor liver transplantation for hepatocellular carcinoma
10.3760/cma.j.issn.0254-1785.2011.06.005
- VernacularTitle:活体肝移植治疗肝细胞癌
- Author:
Ying LUO
;
Wenbin JI
;
Xianjie SHI
;
Weidong DUAN
;
Yurong LIANG
;
Zhiming ZHAO
;
Yongwei CHEN
;
Yang LIU
;
Jiahong DONG
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Living donors;
Liver transplantation;
Prognosis;
Recurrence;
Risk factors
- From:
Chinese Journal of Organ Transplantation
2011;32(6):339-342
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the outcome of living donor liver transplantation(LDLT)for hepatocellular carcinoma(HCC).Methods We retrospectively analyzed the clinical data of 180 patients,who had received LDLT(n=34)or deceased donor liver transplantation(DDLT,n=146)for HCC,compared overall and recurrence-free survival between LDLT and DDLT,and identified the risk factors of tumor recurrence and prognosis by univariate and multivariate analysis.Results The 5-year overall survival and recurrence-free survival rate were 53 % and 58 %,respectively,in DDLT group,and 60 % and 60 %,respectively,in LDLT group.There was no significant difference in overall (P=0.85)and recurrence-free(P=0.89)survival between these two groups.The tumor recurrence rate was 26.5 % in LDLT group,and 17.8 % in DDLT group,respectively(P=0.25).Multivariate COX regression model analysis identified vascular invasion(relative risk 2.118,95 % confidential interval 1.201-4.353,P=0.032)and tumor beyond UCSF criteria(relative risk 3.490,95 % confidential interval 1.862-8.207,P=0.015)as independent risk factors of tumor recurrence,and tumor beyond UCSF criteria(relative risk 8.573,95 % confidential interval 3.016-18.261,P=0.006)as independent predictors of prognosis.Conclusion LDLT is a safe and effective procedure for patients with HCC,but further studies are required for selection criteria of recipients and higher HCC recurrence rate after LDLT.
